MedDataX Logo

Lorcaserin: Real World Experience in an Insurance-Based Weight Management Clinic

NCT ID: NCT03552107

Last Updated: 2019-10-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

157 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-04-11

Study Completion Date

2019-04-11

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a retrospective, descriptive study that involves de-identified data consisting of weight changes, pertinent vital signs and laboratory values influenced by body weight, and healthcare utilization of patients prescribed lorcaserin at The Center for Weight Management at the Scripps Clinic in San Diego, CA.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Lifestyle Modification and Lorcaserin for Weight Loss Maintenance

NCT02388568

Obesity
COMPLETED NA

Pharmacokinetic Properties of Lorcaserin in the Fed and Fasted State

NCT00828724

Obesity
COMPLETED PHASE1

Lorcaserin and Behavioral Modification for Overweight and Obesity Management in Chinese Obese Patients

NCT03720574

Obesity
TERMINATED PHASE3

BLOOM-DM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus

NCT00603291

Obesity
COMPLETED PHASE3

BLOOM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management

NCT00395135

Obesity
COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

All patients who initiated treatment with Lorcaserin during the review period will undergo chart review. The primary endpoint will be weight change in patients on Lorcaserin and average duration of Lorcaserin treatment over time (up to 1 year). Secondary endpoints will include changes in vital signs, liver function, glucose, and lipids. In addition, time on treatment, reasons for discontinuation of medication, and changes in healthcare utilization (to include inpatient and outpatient utilization) will be examined. This is a retrospective, one-arm observational study that will include chart reviews of 157 patients who have been treated in the clinic.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obesity Weight Loss Overweight

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Observational Group - Lorcaserin Treated

The group in this study will be all patients who initiated therapy with Lorcaserin during the review period.

Lorcaserin

Intervention Type DRUG

Treatment initiation with Lorcaserin

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lorcaserin

Treatment initiation with Lorcaserin

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Belviq

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Received at least one prescription for Lorcaserin treatment
* At least 18 years of age or with guardian/parent able to consent for a minor

Exclusion Criteria

\- Patient under the age of 18 at time of index date
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Eisai Inc.

INDUSTRY

Sponsor Role collaborator

Scripps Whittier Diabetes Institute

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Athena Philis-Tsimikas

Corporate Vice President

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ken Fujioka, MD

Role: PRINCIPAL_INVESTIGATOR

Scripps Clinic Medical Group

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Scripps Whittier Diabetes Institute

San Diego, California, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Lorcaserin

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

BLOSSOM: Behavioral Modification and Lorcaserin Second Study for Obesity Management
NCT00603902 COMPLETED PHASE3
3mg Liraglutide for Overweight or Obesity
NCT03885297 COMPLETED
Predictors of Lorcaserin-Induced Weight Loss
NCT03353220 TERMINATED PHASE4
Mass Balance Study of [14C]HRS9531 in Healthy Male Subjects
NCT06855147 COMPLETED PHASE1
In-market Utilisation of Liraglutide Used for Weight Management in Europe
NCT02967757 COMPLETED
The Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes
NCT00422058 COMPLETED PHASE2
To Assess the Effect of Lorcaserin Hydrochloride on Energy Metabolism and Food Intake
NCT00829140 COMPLETED PHASE1
A Multicenter, Double-blind, Randomized, Parallel-group, Pilot Study of 12-week Duration to Assess the Short-term Safety and Tolerability of Lorcaserin Plus Two Doses of Immediate-Release Phentermine-HCl Compared With Lorcaserin Alone in Overweight and Obese Adults
NCT01987427 COMPLETED PHASE4
RWS of of Liraglutide Alone and in Combination With Orlistat for Weight Loss in Overweight/Obese Patients.
NCT07301437 NOT_YET_RECRUITING PHASE4
Weight Loss With Exenatide Treatment
NCT01590433 COMPLETED PHASE4
A Study Of 6-Month Duration To Evaluate The Weight Loss Effect Of Various Doses Of CP-945,598 In Obese Subjects
NCT00134199 COMPLETED PHASE2/PHASE3
A Research Study Looking at New Protein-based Tablets in Healthy Male Participants
NCT05129891 COMPLETED PHASE1
Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in People Who Have a Body Weight Above the Healthy Range
NCT05564117 COMPLETED PHASE3
Safety and Tolerability of Liraglutide in Healthy Japanese Male Volunteers
NCT01515592 COMPLETED PHASE1
Effect of Liraglutide on Weight Loss in Patients Who Have Undergone Revisional Bariatric Surgeries.
NCT05285397 UNKNOWN NA
A Study Evaluating the Effect of Daily Oral RO7795081 in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity
NCT07081958 ACTIVE_NOT_RECRUITING PHASE2
Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus
NCT02453711 COMPLETED PHASE2
Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - Maintenance
NCT00781937 COMPLETED PHASE3
Comparison of Liraglutide Inhaled Into the Lungs Compared to Liraglutide Injected Under the Skin in Healthy Male Volunteers
NCT01511159 COMPLETED PHASE1
Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.
NCT03856047 COMPLETED PHASE2
The Efficacy and Safety of Liraglutide on Body Weight Loss in Obese and Overweight Patients
NCT04605861 COMPLETED PHASE3
Impact of Antiobesity Medications on Appetite and Appetite-related Hormones and Metabolites.
NCT06856928 NOT_YET_RECRUITING
A Study of LY3537021 in Healthy Participants
NCT05444569 COMPLETED PHASE1
A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Non-diabetic Severely Obese Participants
NCT03486392 COMPLETED PHASE2
A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program
NCT04657016 COMPLETED PHASE3